{"changes":[],"country":"US","description":"Targeted-protein-degradation biotech building bifunctional small molecules to drug previously-undruggable proteins. Sells to pharma partners and patient populations with currently inaccessible oncology and immunology targets. Focused on novel ligase recruiters that expand the chemical space of protein degraders beyond the standard CRBN and VHL toolkits.","domain":"ambros.bio","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":"ambros","githubStars":null,"industry":"biotech|therapeutics|pain","investors":[],"lat":33.656752,"lng":-117.733291,"location":"Irvine CA","name":"Ambros Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":125000000,"currency":"USD","date":"2025-12-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-05","status":"attributed","url":null},"status":"attributed","type":"series-a","url":null}],"slug":"ambros-bio","sources":[{"fact":"round","publisher":"crunchbase","retrievedAt":"2026-05-05","status":"attributed","url":null},{"fact":"existence","publisher":"ambros.bio","retrievedAt":"2026-05-05","status":"self-reported","url":"https://ambros.bio"},{"fact":"description","publisher":"ambros.bio","retrievedAt":"2026-05-05","status":"self-reported","url":"https://ambros.bio"}],"stage":"series-a","techStack":[],"totalRaisedUsd":125000000,"updatedAt":"2026-05-05"}